Claims for Patent: 6,723,707

Summary for Patent: 6,723,707

Title:	Use of insulin-like growth factor-I in muscle
Abstract:	The invention relates compositions and method for the use of insulin-like growth factor to enhance muscle mass and strength.
Inventor(s):	Sweeney; H. Lee (Philadelphia, PA), Rosenthal; Nadia A. (Concord, MA)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA) Massachusetts General Hospital (Charlestown, MA)
Application Number:	09/510,268
Patent Claims:	1. An isolated nucleic acid comprising a vertebrate Insulin-like Growth Factor I (IGF-I) coding region, operably linked to a muscle specific promoter/regulatory region, wherein said IGF-I coding region is flanked on the 5' side by an SV40 intron sequence and wherein said IGF-I coding region is flanked on the 3' end by an SV40 polyadenylation signal sequence. 2. The isolated nucleic acid of claim 1, wherein said muscle specific promoter/regulatory region is selected from the group consisting of the myosin light chain 1/3 promoter/enhancer, the skeletal .alpha.-actin promoter, the muscle creatine kinase promoter/enhancer and a muscle specific troponin promoter. 3. The isolated nucleic acid of claim 2, wherein said muscle specific troponin promoter is the fast troponin C promoter/enhancer. 4. The isolated nucleic acid of claim 2, wherein said muscle specific promoter/regulatory region is the myosin light chain 1/3 promoter/enhancer. 5. The isolated nucleic acid of claim 1, wherein said muscle specific promoter/regulatory region further comprises an enhancer element operably linked to the IGF-I coding region. 6. The isolated nucleic acid of claim 5, wherein said enhancer is the myosin light chain 1/3 enhancer. 7. A composition comprising a recombinant virus vector comprising the isolated nucleic acid of claim 6. 8. The composition of claim 7, wherein said recombinant virus vector is selected from the group consisting of an adeno-associated virus, an adenovirus and a herpes simplex virus. 9. The composition of claim 8, wherein said recombinant virus vector is an adeno-associated virus. 10. A cell comprising the isolated nucleic acid of claim 1. 11. A cell comprising the recombinant virus vector of claim 9. 12. A kit for increasing muscle mass and muscle strength in a vertebrate, said kit comprising a muscle enhancing dose of the isolated nucleic acid encoding IGF-I of claim 1, wherein said isolated nucleic acid is expressed in vertebrate muscle cells, and wherein said kit further comprises an applicator for delivering said muscle enhancing dose, and instructions for the use of said kit. 13. A method of increasing vertebrate muscle mass and muscle strength, said method comprising administering a muscle enhancing dose of an isolated nucleic acid encoding Insulin-like Growth Factor I (IGF-I) intramuscularly into a vertebrate, wherein said isolated nucleic acid is expressed in muscle cells, thereby increasing said muscle mass and said muscle strength in said vertebrate, wherein said method further comprising administering to said vertebrate fibroblast growth factor or neurotropin.

Details for Patent 6,723,707

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-08-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-08-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-08-25